SARS-CoV-2 Nucleocapsid anticorps

N° du produit ABIN7794935

Cet anticorps Souris Monoclonal détecte spécifiquement SARS-CoV-2 Nucleocapsid dans . Il présente une réactivité envers SARS Coronavirus-2 (SARS-CoV-2).

Aperçu rapide pour SARS-CoV-2 Nucleocapsid anticorps (ABIN7794935)

Antigène: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Reactivité: SARS Coronavirus-2 (SARS-CoV-2)

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp SARS-CoV-2 Nucleocapsid est non-conjugé

Application: Veuillez nous consulter SVP

Clone: NP1-D6

Détail du produit anti-SARS-CoV-2 Nucleocapsid anticorps

Fonction: Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-D6) Purified No Carrier Protein

Specificité: Anti-SARS-CoV-2 Nucleocapsid, clone NP1-D6, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Futhermore, it is reported to bind to the oligomerization domain of the N protein. Antigen Distribution The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2. Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus belonging to the Coronaviridae family1. The SARS-CoV-2 genome encodes four essential proteins the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2. SARS-CoV-2 shares 79.6 % identity with the original SARS-CoV2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in a couple of primary functions, including RNA binding and self-oligomerization3,4. This results in binding to and packaging of the viral RNA genome into a helical ribonucleoprotein5. The N protein is involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways6,7. The N protein is a suitable candidate for vaccine development and diagnostic assays8 for several reasons. It is abundantly expressed during infection and is highly conserved, sharing 90 % amino acid homology with the SARS-CoV N protein9. Furthermore, antibodies9,10 and memory T cells11,12 targeting the N protein are identified in the sera of convalescent COVID-19 patients, demonstrating it as immunogenic. The N protein also suppresses antiviral RNAi, evading the innate immune system13, suggesting its potential value as a targeted therapeutic.

Purification: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pureté: >=90 % monomer by analytical SEC and SDS-Page

Isotype: IgG1

Information d'application

Restrictions: For Research Use only

Stockage

Concentration: 1 μg/mL

Buffer: This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Agent conservateur: Without preservative

Stock: 4 °C,-80 °C

Stockage commentaire: This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at <= -70°C.Avoid Repeated Freeze Thaw Cycles.

Détails sur SARS-CoV-2 Nucleocapsid

Antigène: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Autre désignation: SARS-CoV-2 Nucleocapsid (N)

Classe de substances: Viral Protein

Sujet: COV2-NP1-D6, SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein,